What question did this study set out to answer?

The aim is to evaluate the effects of GLP-1 receptor agonist therapy on psoriatic arthritis and metabolic outcomes.

April 8, 2026Arthritis & Rheumatology3 citations

Glucagon‐like peptide‐1 receptor agonist therapy is associated with improvement in psoriatic arthritis‐related and metabolic outcomes: A retrospective analysis of two cohorts

RHRebecca H. Haberman ARAlexandra L. Rice KCKyra Chen

Key Points

The aim is to evaluate the effects of GLP-1 receptor agonist therapy on psoriatic arthritis and metabolic outcomes.
Conducted a retrospective analysis of two cohorts receiving GLP-1RA therapy.
Evaluated changes in systemic inflammation, pain, and weight.
Assessed improvements in cardiometabolic markers alongside psoriatic outcomes.
Patients experienced clinically meaningful weight loss with GLP-1RA therapy.
Statistically significant improvements were noted in systemic inflammation and pain.
Improvements in psoriatic outcomes were directly related to the extent of weight loss.

Abstract

In this real-world study, GLP-1RA therapy in PsA was associated with clinically meaningful weight loss and improvements in systemic inflammation, pain, and cardiometabolic markers. Improvements in psoriatic outcomes were proportional to the degree of weight loss. These findings warrant further investigation in prospective controlled studies to evaluate the role of GLP-1RAs in PsA management and comorbidities.

Ask AI

Helpful

Bookmark

View Full Paper